1-5 of 5
Enrique Ocio, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

OP-106 Horizon — Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS

Paul Richardson, Enrique Ocio, MD, Albert Oriol, MD, Alessandra Larocca, MD, Paula Rodriguez Otero, MD, Jan Moreb, MD, Joan Bladé, MD, Hani Hassoun, MD, Michele Cavo, MD, Adrián Alegre, MD, Amitabha Mazumder, MD, Christopher Maisel, MD, Agne Paner, MD, Nashat Gabrail, MD, Jeffrey A Zonder, MD, Dharminder Chauhan, PhD, Johan Harmenberg, MD, Sara Thuresson, MSc, Hanan Zubair, MSc, Maria-Victoria Mateos, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 600.
https://doi.org/10.1182/blood-2018-99-113095
Published: 2018
Journal Articles

The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrmm; First Report on Phase 1 Data

Ludek Pour, MD, Miquel Granell, MD, Roman Hajek, MD PhD, Albert Oriol, MD, Yvonne Efebera, MD, Jacques Delaunay, MD, Katell Le Du, MD, Jean-Richard Eveillard, MD, Lionel Karlin, MD, Vladimir Maisnar, MD, Joaquin Martinez Lopez, MD, Maria-Victoria Mateos, MD PhD, Jan Moreb, MD, Vincent Ribrag, MD, Paul Richardson, Jan Straub, MD, Catriona Byrne, RN, Christian Jacques, MD, Hanan Zubair, MSc, Enrique Ocio, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1967.
https://doi.org/10.1182/blood-2018-99-112983
Published: 2018
Journal Articles

Novel Ex Vivo Assay Measures Drug-Induced Depletion of Hematopoietic Progenitors As an Estimate of Hematotoxicity

Daniel Primo, PhD, Joan Ballesteros, PhD, Antonio Jimenez, MD, Ataulfo Gonzalez, MD, Miguel Hernandez, MD, Raul Cordoba, MD, Yolanda González, MD, Hernan Jose Moreno, MD, Alicia Bailen, MD, Jesus Martin, MD, Anabelle Chinea, MD, Asuncion Etxeveste, MD, Jose Mariano Hernandez, MD, Albert Oriol, MD, Jaime Perez de Oteiza, MD, Luis Palomera, Cristina Encinas, MD, Felipe Prosper, MD, Rebeca Iglesias, MD, Laura Rosiñol, MD PhD, Alicia Robles, Julian Gorrochategui, Veronica Garcia, Pilar Hernandez, PhD, Enrique Ocio, MD, Joaquin Martinez, MD
Journal: Blood
Blood (2014) 124 (21): 5785.
https://doi.org/10.1182/blood.V124.21.5785.5785
Published: 2014
Journal Articles

Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells.

Teru Hideshima, MD, PhD, Hiroshi Yasui, MD, PhD, Laurence Catley, MD, Noopur Raje, MD, Dharminder Chauhan, PhD, Kenji Ishitsuka, MD, PhD, Klaus Podar, MD, PhD, Constantine Mitsiades, MD, PhD, Yu-Tzu Tai, PhD, Sonia Vallet, MD, Tanyel Kizitepe, PhD, Enrique Ocio, MD, PhD, Hiroshi Ikeda, MD, PhD, Yutaka Okawa, MD, PhD, Hiromasa Hideshima, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2006) 108 (11): 3410.
https://doi.org/10.1182/blood.V108.11.3410.3410
Published: 2006
Journal Articles

Perifosine, an Oral Bioactive Novel Akt Inhibitor, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom Macroglobulinemia.

Xavier Leleu, MD, Xiaoying Jia, Anne-Sophie Moreau, MD, Evdoxia Hatjiharisi, MD, Hai Ngo, Garrett O’Sullivan, Daisy Moreno, Tanyel Kiziltepe, PhD, Enrique Ocio, MD, Allen Ho, MD, Thierry Facon, MD, Steven Treon, MD, Teru Hideshima, MD, Kenneth Anderson, MD, Irene Ghobrial, MD
Journal: Blood
Blood (2006) 108 (11): 2488.
https://doi.org/10.1182/blood.V108.11.2488.2488
Published: 2006